Adverse Effects of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Literature Review

    December 2025 in “ International Journal of Innovative Technologies in Social Science ”
    Adrian Kruk, Dominika Walczak, Aleksandra Dorosz … Lidia Jurczenko
    Studysummary This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on rsglobal.pl →
    Discuss this study in the Community →

    Research cited in this study 8

    1. Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance Study The Journal of Dermatology · 2025
    2. Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials Journal of Clinical Medicine · 2025
    3. Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study Journal of the European Academy of Dermatology and Venereology · 2025
    4. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    5. Efficacy and Safety of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, in Adolescent and Adult Patients with Alopecia Totalis and Alopecia Universalis The Journal of Dermatology · 2024
    6. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    7. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    8. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023